Interventional
Conditions
Keywords
Collagen, Vitamin C, Carbohydrate placebo
Brief summary
The primary objective of this study will be to determine the influence of a presleep vitamin C-enriched, collagen-modelled supplement (CVC) on the metabolic fate of dietary glycine using a \[2H5\]glycine tracer within the intramuscular connective tissue at rest and after a bout of resistance exercise. Other outcomes will be related to regulation collagen remodelling in skeletal muscle.
Interventions
DIETARY_SUPPLEMENTCollagen and Vitamin C
Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
DIETARY_SUPPLEMENTCarbohydrate Placebo
Iso-caloric Placebo (30g maltodextrin).
Sponsors
University of Toronto
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Masking description
Double blinded (investigators and participants). A lab member external to the investigation will code items for the intervention.
Intervention model description
Crossover to receive Collagen and Vitamin C (CVC) or Carbohydrate placebo. Unilateral leg exercise (EX) to give 4 outcomes. (1) CVC-EX; (2) CVC-REST; (3) PLACEBO-EX; (4) PLACEBO-REST
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy, recreationally active, male and female participants. * Healthy will be defined as someone who does not have a health condition that would compromise their ability to safely participate in the strenuous physical activity involved in our study as screened for by the Get Active Questionnaire. * Willing to abstain from resistance exercise for 2 weeks prior to the first metabolic trial and for the duration of the study. * Participants must be able to abstain from lower-body resistance and/or plyometric exercise for at least 2 weeks prior to the first metabolic trial. * Participants will be aged 18-35 years old. * Participants must be normal to overweight (e.g., BMI 18.5-30). * Participants are willing to abide by the compliance rules of this study (e.g., abstain from physical activity and alcohol 48h prior to each trial). * Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants).
Exclusion criteria
* Inability to adhere to any of the compliance rules judged by principal investigator or medical doctor. * Self-reported regular tobacco use. * Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.). * Regular use of anti-inflammatory drugs (e.g., ibuprofen). * Self-reported regularly sleeping less than an average of 7 hours over 3 days (minimum recommended daily amount). * Individuals who have participated in studies within the past year involving any of the stable isotopes in the study. * Use of birth control and discontinued use in the last 3-months (female only).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Enrichment of Muscle Collagen | 9 hours | Overnight incorporation of orally ingested amino acid tracer (D5 Gly and D5 Phe) into mature collagen protein isolated from skeletal muscle biopsy samples taken 9 hours after consumption of the tracer-containing supplement (CVC or PLA) and rest or resistance exercise. Enrichment will be quantified via tandem LC-MS/MS. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area of muscle with localized collagen remodelling | 9 hours | Immunofluorescence determined localization of collagen breakdown and synthesis using collagen hybridizing peptide and procollagen antibodies, respectively, on human skeletal muscle cross-sections. |
| Concentration of Urinary Growth Hormone | 8 hours | Urine will be collected overnight to measure growth hormone secretion using chemiluminescence. |
| Enrichment of Myofibrillar Protein | 9 hours | Overnight incorporation of orally ingested amino acid tracer (D5 Gly and D5 Phe) into myofibrillar proteins isolated from skeletal muscle biopsy samples taken 9 hours after consumption of the tracer-containing supplement (CVC or PLA) and rest or resistance exercise. Enrichment will be quantified via tandem LC-MS/MS. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Intensity of Muscle Soreness | 24 hours | Subjective muscle soreness will be quantified using a visual analog scale on trial day mornings and evenings as well as before and after exercise. Using a line spanning 0 to 100 (100 being greatest soreness), participants will select a spot on the line indicating their subjective muscle soreness. |
Countries
Canada
Contacts
Primary ContactDaniel R Moore, PhD
Backup ContactPaul L Babits, BKin
Outcome results
None listed